Company profile: EdenRoc Sciences
1.1 - Company Overview
Company description
- Provider of holding and operating services for bioscience and pharmaceutical startups, managing Metro International Biotech (proprietary NAD boosters), Cantata Bio (NGS-based multiomics tools via Dovetail Genomics and Arc Bio), Claret Bioscience, Astrea Forensics (advanced DNA for casework), Delavie Sciences (consumer care ingredients), and Liberty Biosecurity.
Products and services
- Metro International Biotech LLC: Engineers a clinical-stage portfolio of proprietary NAD boosters, producing pharmaceutical products under active clinical development focused on NAD elevation
- Cantata Bio: Delivers multiomics toolsets through subsidiaries Dovetail Genomics and Arc Bio, offering NGS-based products and services spanning next-generation sequencing
- Delavie Sciences: Develops ingredients and products for the consumer care industry, including Bacillus Lysate-based offerings serving consumer care markets.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to EdenRoc Sciences
Purdue Pharma
HQ: United States
Website
- Description: Provider of medications and consumer health products for healthcare professionals, patients, consumers, and caregivers; develops, manufactures, and markets prescription opioid analgesics for pain management and over-the-counter medications including laxatives, antiseptics, and dietary supplements; offers public health initiatives; and conducts research and development of medications for cancer and central nervous system disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Purdue Pharma company profile →
Fortress Biotech
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, focused on acquiring, developing and commercializing therapeutic products. Pipeline: Cosibelimab (fully human PD-L1 antibody) for EGFR mutation–positive non-small cell lung cancer; DFD-29 for inflammatory lesions of rosacea; IV Tramadol for post-surgical pain; AJ201 for spinal and bulbar muscular atrophy; BAER-101 for CNS disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fortress Biotech company profile →
Insys Therapeutics
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals, developing and commercializing innovative supportive care products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insys Therapeutics company profile →
Amgen
HQ: United States
Website
- Description: Provider of biotechnology-based human therapeutics, including biosimilar medicines for oncology, hematology, and chronic inflammatory diseases, and oncology therapies spanning precision oncology and targeted immunotherapy. Also offers the Amgen Biotech Experience for hands-on secondary school education and supports science education and communities through the Amgen Foundation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amgen company profile →
Paladin Labs
HQ: Canada
Website
- Description: Provider of innovative pharmaceutical products, headquartered in Montreal, Canada, specializing in researching, developing, acquiring, and in-licensing for the Canadian and world markets, supported by a focused national sales team and proven marketing expertise.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paladin Labs company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for EdenRoc Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to EdenRoc Sciences
2.2 - Growth funds investing in similar companies to EdenRoc Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for EdenRoc Sciences
4.2 - Public trading comparable groups for EdenRoc Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →